Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

John M. KaneDepartment of Psychiatry, The Zucker Hillside Hospital and the Hofstra North Shore-LIJ School of Medicine Glen Oaks, NYUSA

Raymond SanchezGlobal Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSA

Joan ZhaoBiostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSA

Anna R. DucaClinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSA

Brian R. JohnsonClinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSA

Robert D. McQuadeGlobal Medical, Regulatory Affairs and Alliances, Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSA

Anna EramoMedical Affairs & Phase IV Clinical Affairs H. Lundbeck A/S, Deerfield, ILUSA

Ross A. BakerCNS Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSACorrespondence[email protected]

Timothy Peters-StricklandGlobal Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJUSA

Your download is now in progress and you may close this window